AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (ATRC) (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, ...
In the third quarter, AtriCure beat consensus estimates on both the top and bottom lines, posting revenue of $134.3 million and a loss of just 1 cent per share versus expectations for an 11-cent loss.
AtriCure posts strong Q4 results with 13% growth to $140.5M, driven by new product adoption. Raises 2026 guidance despite PFA competition.
Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results